Loading...
11β-HSD1 inhibition ameliorates diabetes-induced cardiomyocyte hypertrophy and cardiac fibrosis through modulation of EGFR activity
11β-HSD1 has been recognized as a potential therapeutic target for type 2 diabetes. Recent studies have shown that hyperglycemia leads to activation of 11β-HSD1, increasing the intracellular glucocorticoid levels. Excess glucocorticoids may lead to the clinical manifestations of cardiac injury. Ther...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5707098/ https://ncbi.nlm.nih.gov/pubmed/29221204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22015 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|